Retifanlimab-dlwr
Retifanlimab-dlwr is a type of drug called an immune checkpoint inhibitor. It works by binding to the protein PD-1 on the surface of certain immune cells called T cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack the cancer cells.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Retifanlimab-dlwr is approved to treat adults with:
- Squamous cell anal carcinoma that has spread or come back. It is used:
- With carboplatin and paclitaxel as the first treatment in patients whose cancer cannot be removed by surgery.
- Alone in patients whose cancer has gotten worse while taking platinum chemotherapy or who cannot receive it.
- Merkel cell carcinoma (a type of skin cancer) that has spread or has come back.
Retifanlimab-dlwr is also being studied in the treatment of other types of cancer.
More About Retifanlimab-dlwr
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Retifanlimab-dlwr - A lay language summary of important information about this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Retifanlimab-dlwr - Check for trials from NCI's list of cancer clinical trials now accepting patients.